7. ShangPharma (SHP) is a leading Chinese contract research organization (CRO) for the pharmaceutical and biotechnology industry. The company offers a broad range of integrated services for the discovery and development of drug candidates. ShangPharma will release its 2010 fourth quarter results on Mar. 15.
The company expects year-over-year revenue growth of 26% to 33% for the fourth quarter. For full-year 2010, net revenue is seen in the range of $89.6 to $91.1 million, representing a growth of 24% to 26%. Meanwhile, GAAP gross profit is likely to increase by 24% to 28% to $29.6 to $30.5 million. Gross margins are expected to improve on favorable service mix, effective cost control, proficient material usage, and operational efficiency.
All the five analysts covering the stock recommend a buy. Analysts polled by Bloomberg expect the stock to gain an average 32% to $16.3 from current levels over the next 12 months.